SCHEMBL9976795

SCHEMBL9976795

Nc1cccc(SSSSc2cccc(N)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.52
CASP1 P29466 1/20 0.52
RECQL P46063 1/20 0.52
ALDH1A1 P00352 5/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
CA14 Q9ULX7 2/20 0.42
CA7 P43166 1/20 0.42
MAOA P21397 4/20 0.41
LMNA P02545 2/20 0.38
KDM4E B2RXH2 2/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
ENPP2 Q13822 1/20 0.38
MAOB P27338 4/20 0.37
MAPT P10636 2/20 0.37
CYP19A1 P11511 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34540 0.90 CYP3A4 (0.58) CYP3A4CASP1RECQLALDH1A1CA12
SCHEMBL9976770 0.88 ACHE (0.46) CYP3A4CASP1RECQLALDH1A1CA12
SCHEMBL34658 0.81 CYP3A4 (0.48) CYP3A4CASP1RECQLALDH1A1CA12
SCHEMBL29436321 0.79 CYP3A4 (0.58) CYP3A4CASP1RECQLALDH1A1CA12
SCHEMBL125522 0.79 CYP3A4 (0.58) CYP3A4CASP1RECQLALDH1A1CA12
SCHEMBL1100943 0.77 CYP3A4 (0.55) CYP3A4CASP1RECQLALDH1A1CA12
SCHEMBL13591730 0.77
Benzene SCHEMBL28782155 0.77 CYP3A4 (0.55) CYP3A4CASP1RECQLALDH1A1CA12
SCHEMBL7782781 0.75
SCHEMBL13588996 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202997-B2 Compositions and methods for treating or preventing hypoxic or ischemic injury IKARIA, INC. (US) 2012-06-19 US disclosed
US-8202997-B2 Compositions and methods for treating or preventing hypoxic or ischemic injury IKARIA, INC. (US) 2012-06-19 US disclosed
US-20100130555-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY IKARIA, INC. (US) 2010-05-27 US disclosed
US-20100130555-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY IKARIA, INC. (US) 2010-05-27 US disclosed
WO-2010045582-A2 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY IKARIA, INC. (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130555-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY HIF1AN, HIF1A, HYOU1 CYP3A4 3440/4885CASP1 631/4885RECQL 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.